Testing ziltivekimab after a heart attack
Treatments studied
Part of Heart & circulation clinical trials.
This study tests a new drug called ziltivekimab to see if it helps people who have recently had a heart attack. The drug is given as an injection and compared to a placebo (a shot with no active medicine).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been hospitalized for a heart attack (either STEMI or NSTEMI).
- You have at least one of: a past heart attack, prior heart surgery or stenting, diabetes on medication, chronic kidney disease, prior stroke, carotid or leg artery disease, blockages in multiple heart arteries, or an anterior heart attack (for STEMI).
- You can receive the first dose of the study drug within 36 hours (for STEMI) or 72 hours (for NSTEMI) of being hospitalized.
- You do not have severe heart failure, active infection, severe kidney or liver disease, or untreated tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Ziltivekimab to see if it can reduce plaque buildup in the heart arteries after a heart attack. It may help prevent future heart problems by targeting inflammation.
This trial tests whether giving a powerful cholesterol-lowering drug (PCSK9 inhibitor) very early after a heart attack can help prevent further heart problems. It is for people who have had a recent heart attack and have blockages in more than one heart artery.
This trial is testing a new way to quickly measure the level of a blood thinner (tirofiban) in the blood of people having a heart attack. It aims to make sure the dose is right and safe for each patient.
This trial tests whether combining antioxidant supplements with standard heart attack care can reduce heart muscle damage. It may help people who are getting emergency treatment for their first heart attack.
This trial tests selatogrel to see if it can better prevent harmful heart and blood-clot outcomes after a recent heart attack. You may be considered if you had a heart attack in the past 4 weeks and have higher-risk heart artery disease.
This study tests a drug called ziltivekimab to see if it can reduce fatty plaque buildup in heart arteries after a heart attack. It's for people who had a heart attack treated with a stent and have mild blockages in other arteries.
Hear when a new Cardiovascular Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.